5/9/2025

Janusmed kön och genus

Janusmed kön och genus – Blopresid Comp

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Hydroklortiazid

Hydroklortiazid

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study HANE Trial Research Group. BMJ. 1997;315:154-9.

  2. Fan X, Han Y, Sun K, Wang Y, Xin Y, Bai Y et al. Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension. Ann Pharmacother. 2008;42:1772-81.

  3. Falconnet C, Bochud M, Bovet P, Maillard M, Burnier M. Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J Hypertens. 2004;22:1213-20.

  4. Franson KL, Kuk JM, Lam NP, Lau AH. Gender effect on diuretic response to hydrochlorothiazide and furosemide. Int J Clin Pharmacol Ther. 1996;34:101-5.

  5. Pottegård A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331.

  6. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681e9.

  7. Läkemedelsverket. Hydroklortiazid - Risk för icke-melanom hudcancer (basalcellscancer, skivepitelcancer). Läkemedelsverket [www]. [updated 2019-10-15, cited 2019-03-12].

  8. Kavaru MS, Ahmad M, Amirthalingam KN. Hydrochlorothiazide-induced acute pulmonary edema. Cleve Clin J Med. 1990;57:181-4.

  9. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. CMAJ. 1991;145:28-34.

  10. Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens. 2002;16(9):631-5.

  11. Al Qahtani M, Alshahrani A, Alskaini A, Abukhalid N, Al Johani N, Al Ammari M et al. Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. Saudi J Kidney Dis Transpl. 2013;24(2):281-5.

  12. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002;62(5):1718-23.

  13. Li Y, Yang P, Wu S, Yuan J, Shen C, Wu Y et al. Gender-specific association between ACE gene I/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. Biochem Genet. 2011;49:704-14.

  14. Rochon PA, Anderson GM, Tu JV, Gurwitz JH, Clark JP, Shear NH et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. 1999;47(8):954-9.

  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study HANE Trial Research Group. BMJ. 1997;315:154-9.
  2. Fan X, Han Y, Sun K, Wang Y, Xin Y, Bai Y et al. Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension. Ann Pharmacother. 2008;42:1772-81.
  3. Falconnet C, Bochud M, Bovet P, Maillard M, Burnier M. Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J Hypertens. 2004;22:1213-20.
  4. Franson KL, Kuk JM, Lam NP, Lau AH. Gender effect on diuretic response to hydrochlorothiazide and furosemide. Int J Clin Pharmacol Ther. 1996;34:101-5.
  5. Pottegård A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331.
  6. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681e9.
  7. Läkemedelsverket. Hydroklortiazid - Risk för icke-melanom hudcancer (basalcellscancer, skivepitelcancer). Läkemedelsverket [www]. [updated 2019-10-15, cited 2019-03-12].
  8. Kavaru MS, Ahmad M, Amirthalingam KN. Hydrochlorothiazide-induced acute pulmonary edema. Cleve Clin J Med. 1990;57:181-4.
  9. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. CMAJ. 1991;145:28-34.
  10. Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens. 2002;16(9):631-5.
  11. Al Qahtani M, Alshahrani A, Alskaini A, Abukhalid N, Al Johani N, Al Ammari M et al. Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. Saudi J Kidney Dis Transpl. 2013;24(2):281-5.
  12. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002;62(5):1718-23.
  13. Li Y, Yang P, Wu S, Yuan J, Shen C, Wu Y et al. Gender-specific association between ACE gene I/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. Biochem Genet. 2011;49:704-14.
  14. Rochon PA, Anderson GM, Tu JV, Gurwitz JH, Clark JP, Shear NH et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. 1999;47(8):954-9.
  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]
A A
A A

Kandesartan

Kandesartan

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. Eur J Clin Pharmacol. 1997;53:221-8.

  2. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11 Suppl 2:S19-25.

  3. Atacand (candesartan cilexetil). DailyMed [www]. US National Library of Medicine. [updated 2018-10-01, cited 2019-10-11].

  4. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41:7-17.

  5. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083-90.

  6. Food and Drug Administration (FDA). Atacand (candesartan). Drugs@FDA [www]. [updated 2002-04-11, cited 2019-10-11].

  7. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens. 1997;11 Suppl 2:S49-53.

  8. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.

  9. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.

  10. Gleiter CH, Jägle C, Gresser U, Mörike K. Candesartan. Cardiovasc Drug Rev. 2004;22:263-84.

  11. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11 Suppl 2:S69-73.

  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. Eur J Clin Pharmacol. 1997;53:221-8.
  2. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11 Suppl 2:S19-25.
  3. Atacand (candesartan cilexetil). DailyMed [www]. US National Library of Medicine. [updated 2018-10-01, cited 2019-10-11].
  4. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41:7-17.
  5. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083-90.
  6. Food and Drug Administration (FDA). Atacand (candesartan). Drugs@FDA [www]. [updated 2002-04-11, cited 2019-10-11].
  7. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens. 1997;11 Suppl 2:S49-53.
  8. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.
  9. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.
  10. Gleiter CH, Jägle C, Gresser U, Mörike K. Candesartan. Cardiovasc Drug Rev. 2004;22:263-84.
  11. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11 Suppl 2:S69-73.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]